Inhibition of terminal complement complex formation alleviates murine antibody-mediated TRALI
- PMID: 40388640
- DOI: 10.1182/blood.2024028012
Inhibition of terminal complement complex formation alleviates murine antibody-mediated TRALI
Abstract
Transfusion-related acute lung injury (TRALI) is a leading cause of blood transfusion-triggered mortality. Recently, we demonstrated the critical role of Fc-dependent complement activation in anti-CD36-mediated murine TRALI. In this study, we found that C5-/- mice were protected, and administration of anti-C5 rescued wild-type mice from anti-CD36-mediated TRALI. However, C5aR1-/- mice were not protected against anti-CD36-mediated TRALI, implying a possible role of C5b-9 (membrane attack complex [MAC]). Accordingly, elevated levels of MAC were detected in bronchoalveolar lavage fluid and lung tissue of mice with anti-CD36-induced TRALI. Inhibition of MAC formation by administration of anti-C7-blocking monoclonal antibody alleviated TRALI in mice, suggesting the critical role of the MAC in the pathology of anti-CD36-mediated TRALI. Furthermore, anti-C7 treatment also led to favorable outcome in murine TRALI induced by anti-major histocompatibility complex class 1, indicating the potential broader applicability of MAC inhibitors in the treatment of antibody-mediated TRALI. Therefore, this approach may be promising to further explore the treatment of patients with TRALI.
© 2025 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.
Comment in
-
Cracking TRALI: targeting the membrane attack complex.Blood. 2025 Aug 7;146(6):658-660. doi: 10.1182/blood.2025029798. Blood. 2025. PMID: 40773176 No abstract available.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous